IN THE UNITED STAFFES PATENT AND TRADEMARK OFFICE

1FW)

In re Patent Application of

LEVIN et al.

Atty. Ref.: 4343-3

Serial No. 10/808,397

Group: 3736

Filed: March 25, 2004

Examiner: Not yet assigned

For:

METHOD AND SYSTEM TO TREAT AND PREVENT

SEP 1 9 2005

MYOCARDIAL INFARCT EXPANSION

September 19, 2005

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

INFORMATION DISCLOSURE STATEMENT

\boxtimes	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action]	N/C				
	2.	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]	N/C				
	3.	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance]	\$180.00				
	4.	Statement & Fee Payment Pursuant to 37 CFR 1.97(d) [before Issue Fee payment]	\$180.00				
\boxtimes	5.	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document is enclosed herewith.					
This p	paper i	s submitted in accordance with:					
\boxtimes	6.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st 0	Office Action]				
	7.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and					
		a) The Statement required by 37 CFR 881 97(c)(1) and ((e) made in item 0 helow: or				

		b)	The fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.					
	8.	37 C	37 CFR §1.97(d): [before issue fee payment]; and					
		a)	This is a request for consideration of the subject Information Disclosure Statement. The fee required by 37 CFR §1.17(p) is authorized in item 10 below; and					
		b)	The Statement required by 37 CFR §§1.97(d)(1) and (e) is stated in item 9 below					
	9.	Statement under 37 CFR 1.97(e)						
		a)	Each item of information contained in this Information Disclosure Statement was cited for the first time in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or					
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
	10.	Disc	lease charge all applicable fees associated with the submission of this Information isclosure Statement and any other fees applicable to this application to Deposit count No. 14-1140. An original and one (1) copy of this document are enclosed.					
		Respectfully submitted,						
		NIXON & VANDERHYE P.C.						
			By: Jeffry H. Nelson					
JHN:g	ılf		Reg. No. 30,481					
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,11							

JHN:glf 1100 North Glebe Road, 8th Floor Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

SEP 1 9 2005

Sheet 1 of 1

INFORMATION DISCLOSURES OF TY. DOCKET NO.

SERIAL NO.

CITATION

(Use several sheets if necessary)

4343-3 APPLICANT 10/808,397

LEVIN et al.

GROUP

March 25, 2004

3736

Form PTO-FB-A820 (Also PTO-1449)

			<u> </u>	3736						
			J.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		DATE OPRIATE			
	5,702,343	12/30/1997	Alferness							
	6,077,218	06/20/2000	Alferness							
	6,085,754	07/11/2000	Alferness et al.							
	6,123,662	09/26/2000	Alferness et al.							
	6,126,590	10/03/2000	Alferness							
	6,155,972	12/05/2000	Nauertz et al.							
	6,165,121	12/26/2000	Alferness							
	6,165,122	12/26/2000	Alferness							
	6,174,279	01/16/2001	Girard							
	6,193,648	02/27/2001	Krueger							
	6,241,654	06/05/2001	Alferness							
	6,293,906	09/25/2001	Vanden Hoek et al.							
	6,332,863	12/25/2001	Schweich, Jr. et al.							
	6,332,864	12/25/2001	Schweich, Jr. et al.							
	6,375,608	04/23/2002	Alferness							
	6,402,679	06/11/2002	Mortier et al.							
	6,402,680	06/11/2002	Mortier et al.			i -				
	6,416,459	07/09/2002	Haindl							
	6,425,856	07/30/2002	Shapland et al.							
	6,482,146	11/19/2002	Alferness et al.							
	6,494,825	12/17/2002	Talpade							
	6,463,332	10/08/2002	Aldrich							
		FC	REIGN PATENT DOCUMENTS	<u> </u>	<u> </u>					
						TRANS	LATION			
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO			
	OTHER DO	CUMENTS (including Author, Title, Date, Pertin	ent pages,	etc.)		_			
	CORCAP Brochure, 2 pages (2004)									
	CORCAP Power Point Presentation, 8 pages (No Date)									
		Scott T. Kelley, MD et al, "Restraining Infarct Expansion Preserves Left Ventricular Geometry and Function After Acute Anteroapical								
	Infarction", pp. 135-142 James J. Pilla, PhD, et al., "Ventricular Constraint Using the Acorn Cardiac Support Device Reduces Myocardial Akine									
	Ovine Model of Acute Infarction", pp. I-207 – I-211									
*Examiner			Date Considered	1						

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.